Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The awards link equity vesting to continued employment or other service over three years.

Rhea-AI Summary

Intellia Therapeutics (NTLA) awarded employment inducement equity grants to Executive Vice President and Chief Medical Officer Jing Marantz on October 26, 2026.

The awards comprise options to purchase 275,061 shares at an exercise price of $11.26 per share and restricted stock units covering 199,822 shares. The option exercise price equals the closing share price on the grant date. Both awards vest over three years, subject to continued employment or other service through each applicable vesting date. A majority of independent directors approved the grants under Nasdaq Listing Rule 5635(c)(4). They were issued outside stockholder-approved equity incentive plans under the amended 2024 Inducement Plan.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.275,061 stock options at $11.26 per share create potential dilution upon vesting and exercise.
• Minor point. Forward-looking: it has not happened yet and may not happen.199,822 restricted stock units create potential dilution, with vesting subject to continued employment or other service.

Key Figures

Option award: 275,061 shares Option exercise price: $11.26 per share RSU award: 199,822 shares +1 more

Option award

275,061 shares

Non-qualified stock options

Option exercise price

$11.26 per share

Options granted October 26, 2026

RSU award

199,822 shares

Time-based restricted stock units

Vesting schedule

One-third annually over three anniversaries

RSU award; subject to continued service

Historical Context

2 past events · Latest: Oct 02

2 events

1. Oct 02

   Inducement grants

   24h Move

   +4.0%

   Earlier 44,450-share employee grants under the same plan used annual vesting over three years.

2. Sep 04

   Inducement grants

   24h Move

   +0.0%

   The company granted 163,100 RSU shares to 41 employees under the same plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, restricted stock units, crispr gene editing, nasdaq listing rule 5635(c)(4)

4 terms

non-qualified stock options financial

"non-qualified stock options to purchase 275,061 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"time-based restricted stock units (“RSUs”) for 199,822 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

crispr gene editing technical

"revolutionizing medicine leveraging CRISPR gene editing"

CRISPR gene editing is a laboratory technique that uses a guided molecular “scissor” to change DNA at specific locations, allowing scientists to add, remove, or correct genetic code. For investors, it matters because it underpins a new class of therapies and biotech products with high upside if they work, but also carries long development timelines, regulatory uncertainty, and technical risks that can create large swings in company value.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it awarded inducement grants on October 26, 2026, to its Executive Vice President and Chief Medical Officer, Jing Marantz, M.D., Ph.D., as a material inducement to employment.

The inducement grants consisted of (1) non-qualified stock options to purchase 275,061 shares of Intellia’s common stock with an exercise price of $11.26 per share (the “option award”), the closing price of Intellia’s common stock as reported by Nasdaq Global Market on October 26, 2026, with one-third of the options underlying the option award vesting on the first anniversary of the grant date and the remainder vesting monthly thereafter until fully vested on the third anniversary of the grant date and (2) time-based restricted stock units (“RSUs”) for 199,822 shares of Intellia’s common stock (the “RSU award”), with one-third of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date.

All equity vesting is subject to Dr. Marantz’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by a majority of the independent directors of Intellia’s board of directors as a material inducement to Dr. Marantz’s entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity inducement grants did Intellia award Jing Marantz?

Intellia awarded Marantz options to purchase 275,061 shares at $11.26 per share and restricted stock units covering 199,822 shares. The grants were awarded on October 26, 2026, as a material inducement to employment.

How do Jing Marantz’s Intellia inducement grants vest?

One-third of the options vest on the grant date’s first anniversary, with the remainder vesting monthly until the third anniversary; one-third of the restricted stock units vest on each of the three consecutive anniversaries.

All vesting requires Marantz to remain an employee or other service provider through the applicable vesting dates.